Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (212)	12/3/1999 9:30:00 AM
From: Softechie	Respond to of 743

AVNR latest financing synopsis from Yahoo post. -------------------- Overall it's a fair deal by: beans_counter (60/M/Malaysia) 12/1/1999 12:57 am EST Msg: 19091 of 19299 1) Avanir received $1.5M cash infusion now. This is much needed to keep operation running while we're negotiating with 8 pharma companies. 2) If 389408 shares (2/3 of 584112) were exercised fully in the last few days of trading, then financial institutions will gain about $236K to $240K profits. 3) Avanir will gain another $500K from this exercise to bring them to $2M in the bank. Total outstanding shares will increase by 389,408. 4) We have until 3/6/2000 to repay the $1.5M loan plus 11% interest. This is very doable. I'm not sure when the other 194,704 shares (1/3) will expire. If we pay on time will they go away? 5) Class D warrants will not get extended past 12/31/1999. If these are fully exercised then Avanir will get another $2.1M in the coffer. Total outstanding shares will increase by 152,728 shares. In total we will have at least $4M in the bank at the end of the year and hopefully $4/share so we can file to get relisted on NASDAQ Small Cap Market.

To: scaram(o)uche who wrote (212)	12/3/1999 10:18:00 AM
From: luis a. garcia	Read Replies (1) \| Respond to of 743

Richard you don't need to like the stock and you can critize it, that is allright. But this stock is turned the corner and we think is going higher. the company just secured a bridge loan and is currently in talks with 8 different pharmas for royalty and distribution rights. this will happen. We are in a new ball game here. the drug is global and there are partners in europe and the middle east. this drug utility was just affirmed and secured by patents.. see latest news. It is effective for cold sores, GENITAL herpes I, II, kaposi, keloid skin disorders, burns. Maybe even usefull during intercourse as an aids prevention. I mean there is a lot to like here. first drug coming to market the fundamentals are shot like every small biotechs with their first blockbuster drug after yrs of fighting with fda for approval. so what? stay tuned this will happen.... luis